Polo-like Kinases and Acute Leukemia

Overview

Journal Oncogene

Specialties Molecular Biology
Oncology

Date 2018 Aug 15

PMID 30104712

Citations 25

Authors

Oksana Goroshchuk

Iryna Kolosenko

Linda Vidarsdottir

Alireza Azimi

Caroline Palm-Apergi

Affiliations

Soon will be listed here.

Abstract

Acute leukemia is a common malignancy among children and adults worldwide and many patients suffer from chronic health issues using current therapeutic approaches. Therefore, there is a great need for the development of novel and more specific therapies with fewer side effects. The family of Polo-like kinases (Plks) is a group of five serine/threonine kinases that play an important role in cell cycle regulation and are critical targets for therapeutic invention. Plk1 and Plk4 are novel targets for cancer therapy as leukemic cells often express higher levels than normal cells. In contrast, Plk2 and Plk3 are considered to be tumor suppressors. Several small molecule inhibitors have been developed for targeting Plk1 inhibition. Despite reaching phase III clinical trials, one of the ATP-competitive Plk1 inhibitor, volasertib, did not induce an objective clinical response and even caused lethal side effects in some patients. In order to improve the specificity of the Plk1 inhibitors and reduce off-target side effects, novel RNA interference (RNAi)-based therapies have been developed. In this review, we summarize the mechanisms of action of the Plk family members in acute leukemia, describe preclinical studies and clinical trials involving Plk-targeting drugs and discuss novel approaches in Plk targeting.

Citing Articles

PLK1 inhibition impairs erythroid differentiation.

Jia P, Li Y, Duan L, Zhang J, Xu Y, Zhang H Front Cell Dev Biol. 2025; 12:1516704.

PMID: 39763588 PMC: 11701054. DOI: 10.3389/fcell.2024.1516704.

Only Infant -Rearranged Leukemia Is Susceptible to an Inhibition of Polo-like Kinase 1 (PLK-1) by Volasertib.

Fischer J, Erkner E, Radszuweit P, Hentrich T, Keppeler H, Korkmaz F Int J Mol Sci. 2024; 25(23).

PMID: 39684470 PMC: 11641557. DOI: 10.3390/ijms252312760.

Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review.

Lara P, Quinonero F, Ortiz R, Prados J, Melguizo C Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2024; 16(6):e2013.

PMID: 39510122 PMC: 11655426. DOI: 10.1002/wnan.2013.

A Comprehensive Review of Small Interfering RNAs (siRNAs): Mechanism, Therapeutic Targets, and Delivery Strategies for Cancer Therapy.

Zhang J, Chen B, Gan C, Sun H, Zhang J, Feng L Int J Nanomedicine. 2023; 18:7605-7635.

PMID: 38106451 PMC: 10725753. DOI: 10.2147/IJN.S436038.

Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment.

Peroni E, Randi M, Rosato A, Cagnin S J Exp Clin Cancer Res. 2023; 42(1):259.

PMID: 37803464 PMC: 10557350. DOI: 10.1186/s13046-023-02841-8.

References

Bassan R, Hoelzer D . Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011; 29(5):532-43. DOI: 10.1200/JCO.2010.30.1382. View

Valsasina B, Beria I, Alli C, Alzani R, Avanzi N, Ballinari D . NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies. Mol Cancer Ther. 2012; 11(4):1006-16. DOI: 10.1158/1535-7163.MCT-11-0765. View

Tao Y, Li Z, DU W, Xu L, Ren J, Li X . Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. Oncol Rep. 2017; 37(3):1419-1429. PMC: 5364848. DOI: 10.3892/or.2017.5417. View

Gjertsen B, Schoffski P . Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy. Leukemia. 2014; 29(1):11-9. PMC: 4335352. DOI: 10.1038/leu.2014.222. View

Archambault V, Normandin K . Several inhibitors of the Plk1 Polo-Box Domain turn out to be non-specific protein alkylators. Cell Cycle. 2017; 16(12):1220-1224. PMC: 5499904. DOI: 10.1080/15384101.2017.1325043. View

Bahassi E, Myer D, McKenney R, Hennigan R, Stambrook P . Priming phosphorylation of Chk2 by polo-like kinase 3 (Plk3) mediates its full activation by ATM and a downstream checkpoint in response to DNA damage. Mutat Res. 2006; 596(1-2):166-76. DOI: 10.1016/j.mrfmmm.2005.12.002. View

Kazazian K, Go C, Wu H, Brashavitskaya O, Xu R, Dennis J . Plk4 Promotes Cancer Invasion and Metastasis through Arp2/3 Complex Regulation of the Actin Cytoskeleton. Cancer Res. 2016; 77(2):434-447. DOI: 10.1158/0008-5472.CAN-16-2060. View

Spaniol K, Boos J, Lanvers-Kaminsky C . An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies. Anticancer Drugs. 2011; 22(6):531-42. DOI: 10.1097/CAD.0b013e3283454526. View

Nielsen S, Eriksson F, Rosthoej S, Andersen M, Forestier E, Hasle H . Children with low-risk acute lymphoblastic leukemia are at highest risk of second cancers. Pediatr Blood Cancer. 2017; 64(10). DOI: 10.1002/pbc.26518. View

10.

Armstrong G, Kawashima T, Leisenring W, Stratton K, Stovall M, Hudson M . Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol. 2014; 32(12):1218-27. PMC: 3986385. DOI: 10.1200/JCO.2013.51.1055. View

11.

Talati C, Griffiths E, Wetzler M, Wang E . Polo-like kinase inhibitors in hematologic malignancies. Crit Rev Oncol Hematol. 2015; 98:200-10. DOI: 10.1016/j.critrevonc.2015.10.013. View

12.

Syed N, Smith P, Sullivan A, Spender L, Dyer M, Karran L . Transcriptional silencing of Polo-like kinase 2 (SNK/PLK2) is a frequent event in B-cell malignancies. Blood. 2005; 107(1):250-6. DOI: 10.1182/blood-2005-03-1194. View

13.

Li Z, Dai K, Wang C, Song Y, Gu F, Liu F . Expression of Polo-Like Kinase 4(PLK4) in Breast Cancer and Its Response to Taxane-Based Neoadjuvant Chemotherapy. J Cancer. 2016; 7(9):1125-32. PMC: 4911880. DOI: 10.7150/jca.14307. View

14.

Simmons D, Neel B, Stevens R, Evett G, Erikson R . Identification of an early-growth-response gene encoding a novel putative protein kinase. Mol Cell Biol. 1992; 12(9):4164-9. PMC: 360319. DOI: 10.1128/mcb.12.9.4164-4169.1992. View

15.

Normandin K, Lavallee J, Futter M, Beautrait A, Duchaine J, Guiral S . Identification of Polo-like kinase 1 interaction inhibitors using a novel cell-based assay. Sci Rep. 2016; 5:37581. PMC: 5118709. DOI: 10.1038/srep37581. View

16.

Tontsch-Grunt U, Rudolph D, Waizenegger I, Baum A, Gerlach D, Engelhardt H . Synergistic activity of BET inhibitor BI 894999 with PLK inhibitor volasertib in AML in vitro and in vivo. Cancer Lett. 2018; 421:112-120. DOI: 10.1016/j.canlet.2018.02.018. View

17.

De Kouchkovsky I, Abdul-Hay M . 'Acute myeloid leukemia: a comprehensive review and 2016 update'. Blood Cancer J. 2016; 6(7):e441. PMC: 5030376. DOI: 10.1038/bcj.2016.50. View

18.

Oliveira J, Pezuk J, Brassesco M, Morales A, Queiroz R, Scrideli C . PLK1 expression and BI 2536 effects in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2014; 61(7):1227-31. DOI: 10.1002/pbc.24978. View

19.

Muller-Tidow C, Bug G, Lubbert M, Kramer A, Krauter J, Valent P . A randomized, open-label, phase I/II trial to investigate the maximum tolerated dose of the Polo-like kinase inhibitor BI 2536 in elderly patients with refractory/relapsed acute myeloid leukaemia. Br J Haematol. 2013; 163(2):214-22. DOI: 10.1111/bjh.12518. View

20.

Scharow A, Knappe D, Reindl W, Hoffmann R, Berg T . Development of Bifunctional Inhibitors of Polo-Like Kinase 1 with Low-Nanomolar Activities Against the Polo-Box Domain. Chembiochem. 2015; 17(8):759-67. DOI: 10.1002/cbic.201500535. View